TABLE 1.
Patient characteristics.
| All patients (n = 62) | Standard dose group (n = 49) | Early dose reduction group (n = 13) | p‐value | |
|---|---|---|---|---|
| Age, median (range) | 73 (34–89) | 72 (50–85) | 77 (34–89) | 0.446 |
| <75 years | 34 (54.8%) | 29 (59.2%) | 5 (38.5%) | 0.220 |
| ≥75 years | 28 (45.2%) | 20 (40.8%) | 8 (61.5%) | |
| Sex | ||||
| Male | 23 (37.1%) | 18 (36.7%) | 5 (38.5%) | 1.000 |
| Female | 39 (62.9%) | 31 (63.3%) | 8 (61.5%) | |
| Performance status | ||||
| 0, 1 | 55 (88.7%) | 43 (87.8%) | 12 (92.3%) | 1.000 |
| 2–4 | 7 (11.3%) | 6 (12.2%) | 1 (7.7%) | |
| Smoking status | ||||
| Current/Former | 24 (38.7%) | 18 (36.7%) | 6 (46.2%) | 0.541 |
| Never | 38 (61.3%) | 31 (63.3%) | 7 (53.8%) | |
| Histology | ||||
| Adenocarcinoma | 62 (100%) | 49 (100%) | 13 (100%) | NA |
| Non‐adenocarcinoma | 0 (0%) | 0 (0%) | 0 (0%) | |
| EGFR | ||||
| Exon 19 del | 35 (56.5%) | 24 (49.0%) | 11 (84.6%) | 0.086 |
| Exon 21 L858R | 22 (35.5%) | 20 (40.8%) | 2 (15.4%) | |
| Uncommon | 5 (8.0%) | 5 (10.2%) | 0 (0%) | |
| Body surface area (m2), median (range) | 1.45 (1.06–1.75) | 1.60 (1.06–1.99) | 1.49 (1.19–1.75) | 0.139 |
| Brain metastases before treatment | ||||
| Yes | 17 (27.4%) | 13 (26.5%) | 4 (30.8%) | 0.739 |
| No | 45 (72.6%) | 36 (73.5%) | 9 (69.2%) |
Abbreviations: EGFR, epidermal growth factor receptor; Ex 19del, exon 19 deletion; Ex 21L858R, exon 21 L858R point mutation; NA, not available.